I agree that this site is using cookies. You can find further informations here.
X
Nuthalapati, Silpa
26  results:
Search for persons X
?
1

Impact of COVID‐19 on the Conduct and Design of Clinical Tr..:

Mohamed, Mohamed‐Eslam F. ; Girish, Sandhya ; Humeniuk, Rita...
Clinical Pharmacology & Therapeutics.  116 (2024)  1 - p. 26-29 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Exposure‐Response Model With Time‐Varying Predictors to Est..:

Stodtmann, Sven ; Eckert, Doerthe ; Joshi, Rujuta...
The Journal of Clinical Pharmacology.  62 (2022)  10 - p. 1236-1246 , 2022
Link: https://doi.org/10.1002/..
 
?
3

Eftozanermin alfa (ABBV-621) monotherapy in patients with p..:

LoRusso, Patricia ; Ratain, Mark J. ; Doi, Toshihiko...
Investigational New Drugs.  40 (2022)  4 - p. 762-772 , 2022
Link: https://doi.org/10.1007/..
 
?
4

Veliparib and nivolumab in combination with platinum double..:

Clarke, Jeffrey M. ; Patel, Jyoti D. ; Robert, Francisco...
Lung Cancer.  161 (2021)  - p. 180-188 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Veliparib in combination with carboplatin/paclitaxel-based ..:

Kozono, David E. ; Stinchcombe, Thomas E. ; Salama, Joseph K....
Lung Cancer.  159 (2021)  - p. 56-65 , 2021
Link: https://doi.org/10.1016/..
 
?
6

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a ..:

Stodtmann, Sven ; Nuthalapati, Silpa ; Eckert, Doerthe...
The Journal of Clinical Pharmacology.  61 (2021)  9 - p. 1195-1205 , 2021
Link: https://doi.org/10.1002/..
 
?
7

A first-in-human, phase 1, dose-escalation study of ABBV-17..:

Lemech, Charlotte ; Woodward, Natasha ; Chan, Nancy...
Investigational New Drugs.  38 (2020)  6 - p. 1815-1825 , 2020
Link: https://doi.org/10.1007/..
 
?
8

AML-058: First-In-Human Study of a Trail Receptor Agonist F..:

Jongen-Lavrencic, Mojca ; Yuda, Junichiro ; Mous, Rogier...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S177 , 2020
Link: https://doi.org/10.1016/..
 
?
9

Exposure–response analysis to inform the optimal dose of ve..:

Nuthalapati, Silpa ; Stodtmann, Sven ; Shepherd, Stacie Peacock...
Cancer Chemotherapy and Pharmacology.  84 (2019)  5 - p. 977-986 , 2019
Link: https://doi.org/10.1007/..
 
?
10

Industry Perspective on Standardizing Food-Effect Studies f..:

Marroum, Patrick J. ; Nuthalapati, Silpa ; Parikh, Apurvasena...
Clinical Pharmacokinetics.  57 (2018)  8 - p. 901-909 , 2018
Link: https://doi.org/10.1007/..
 
?
11

Development of a Level A in Vitro-in Vivo Correlation for V..:

Mittapalli, Rajendar K. ; Nuthalapati, Silpa ; Delke DeBord, Alyssa E..
Pharmaceutical Research.  34 (2017)  6 - p. 1187-1192 , 2017
Link: https://doi.org/10.1007/..
 
?
12

Clinical Pharmacokinetics and Mass Balance of Veliparib in ..:

Nuthalapati, Silpa ; Munasinghe, Wijith ; Giranda, Vincent.
Clinical Pharmacokinetics.  57 (2017)  1 - p. 51-58 , 2017
Link: https://doi.org/10.1007/..
 
?
13

Phase 1 study of veliparib with carboplatin and weekly pacl..:

Nishio, Shin ; Takekuma, Munetaka ; Takeuchi, Satoshi...
Cancer Science.  108 (2017)  11 - p. 2213-2220 , 2017
Link: https://doi.org/10.1111/..
 
?
14

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mu..:

Mittapalli, Rajendar K. ; Nuthalapati, Silpa ; Shepherd, Stacie Peacock.
Cancer Chemotherapy and Pharmacology.  79 (2017)  3 - p. 587-594 , 2017
Link: https://doi.org/10.1007/..
 
?
15

Phase 1 dose‐escalation study of single‐agent veliparib in ..:

Nishikawa, Tadaaki ; Matsumoto, Koji ; Tamura, Kenji...
Cancer Science.  108 (2017)  9 - p. 1834-1842 , 2017
Link: https://doi.org/10.1111/..
 
1-15